NCT00443287 - Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease | Biotech Hunter

Enrollment

553

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Intermittent Claudication

Interventions

DRUG

ataciguat (HMR1766)

oral administration

DRUG

placebo

oral administration

DRUG

cilostazol

oral administration

Trial Locations (7)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Midrand